Jasper Therapeutics annual return on equity
2021
2022
2023
2024
2025
Jasper Therapeutics Return on Equity (ROE) Growth & History (JSPR)
Jasper Therapeutics's return on equity was −230.31% for fiscal 2025.
View full Jasper Therapeutics company overviewJasper Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −230.31% | −128.58 pp |
| 2024 | 2024-12-31 | −101.73% | +10.94 pp |
| 2023 | 2023-12-31 | −112.67% | −41.24 pp |
| 2022 | 2022-12-31 | −71.44% | +106.75 pp |
| 2021 | 2021-12-31 | −178.18% | — |
Jasper Therapeutics quarterly return on equity
Q1.20
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −114.69% | −33.40 pp |
| Q1 2026 | 2026-03-31 | −31.10% | +9.79 pp |
| Q4 2025 | 2025-12-31 | −115.77% | −82.31 pp |
| Q3 2025 | 2025-09-30 | −106.84% | −86.58 pp |
| Q2 2025 | 2025-06-30 | −81.29% | −67.63 pp |
| Q1 2025 | 2025-03-31 | −40.88% | −26.56 pp |
| Q4 2024 | 2024-12-31 | −33.46% | −14.25 pp |
| Q3 2024 | 2024-09-30 | −20.26% | −3.09 pp |
| Q2 2024 | 2024-06-30 | −13.66% | +0.00 pp |
| Q1 2024 | 2024-03-31 | −14.32% | +3.37 pp |
| Q4 2023 | 2023-12-31 | −19.22% | +12.41 pp |
| Q3 2023 | 2023-09-30 | −17.17% | +5.14 pp |
| Q2 2023 | 2023-06-30 | −13.66% | +2.74 pp |
| Q1 2023 | 2023-03-31 | −17.69% | −14.49 pp |
| Q4 2022 | 2022-12-31 | −31.62% | — |
| Q3 2022 | 2022-09-30 | −22.31% | +3.93 pp |
| Q2 2022 | 2022-06-30 | −16.40% | — |
| Q1 2022 | 2022-03-31 | −3.21% | — |
| Q3 2021 · Sep 30 | 2021-09-30 | −26.25% | — |
| Q1 2020 | 2020-03-31 | 28.58% | — |
Jasper Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Jasper Therapeutics's return on equity decreased from −178.18% to −230.31%, a change of −52.13 percentage points. The latest reported quarter, Q2 2026, shows −114.69%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Jasper Therapeutics source filings ↗